#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 9 '26)

 

Ann Intern Med

1. CHEN V, Glatt AE
   In older adults, mRNA-1010 vs. a licensed standard-dose influenza vaccine reduced influenza A- or B-related ILI at a median 181 d.
   Ann Intern Med. 2026 Aug 4. doi: 10.7326/ANNALS-26-02527.
   PubMed         Abstract available
   
   

   
   Antimicrob Agents Chemother

2. SUN Z, Huang Y, Guo R, Jiang T, et al
   Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway.
   Antimicrob Agents Chemother. 2026;70:e0197225.
   PubMed         Abstract available
   
   
3. RODRIGUEZ L, Andreatta K, Chen S, Hu Y, et al
   Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19.
   Antimicrob Agents Chemother. 2026;70:e0191225.
   PubMed         Abstract available
   
   

   
   Antiviral Res

4. WANG K, Gibbons JS, Bisht N, Reyes AC, et al
   SARS-CoV-2 resistance pathways to EDP-235.
   Antiviral Res. 2026;253:106493.
   PubMed         Abstract available
   
   
5. WU R, Wang H, Yin R, Gemingnuer A, et al
   Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.
   Antiviral Res. 2026;253:106482.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

6. CHEN H, Fan Y, Huang Y
   Epidemiological characteristics and seasonal dynamics of six respiratory pathogens in children: a 2-year retrospective cross-sectional study in Chengdu, China.
   BMC Pediatr. 2026;26:718.
   PubMed         Abstract available
   
   
7. AMPOFO K, Heller E, Platt-Koch A, Gesteland P, et al
   Burden of laboratory-confirmed RSV hospitalization in children <5 years-of-age; 2019-2022.
   BMC Pediatr. 2026;26:706.
   PubMed         Abstract available
   
   

   
   J Immunol

8. ACKLAND J, Barozi V, Penrice-Randal R, Hartley C, et al
   Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes.
   J Immunol. 2026;215:vkag189.
   PubMed         Abstract available
   
   
9. SILVA JDC, Almeida C, Silva BMS, Bonfim BS, et al
   Elastase and myeloperoxidase participate in neutrophil extracellular trap release stimulated by SARS-CoV-2.
   J Immunol. 2026;215:vkaf313.
   PubMed         Abstract available
   
   

   
   J Infect Dis

10. SMITH D, Weir IR, Ramirez S, Coelho CH, et al
    Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
    J Infect Dis. 2026 Feb 17:jiag091. doi: 10.1093.
    PubMed         Abstract available
    
    
11. PLATT AP, Callier V, Grazioli A, Hu Z, et al
    Association of Plasma Biomarkers of Immunothrombosis With Death in Patients With Coronavirus Disease 2019 on Extracorporeal Membrane Oxygenation.
    J Infect Dis. 2026;234:e40-e53.
    PubMed         Abstract available
    
    
12. SANGIORGIO G, Chamberlin G, Castagnoli R, Wachter B, et al
    Immune-Based Cytokine Signatures of Prolonged Pandemic-Associated Chilblains.
    J Infect Dis. 2026;234:e29-e33.
    PubMed         Abstract available
    
    
13. JAYAWARDENA I, Dean NE, Witrick B, Litwin AH, et al
    2024-2025 COVID-19 mRNA Vaccine Effectiveness against Severe Disease.
    J Infect Dis. 2026 Mar 2:jiag137. doi: 10.1093.
    PubMed         Abstract available
    
    
14. ROSAS-SALAZAR C, Gebretsadik T, Chappell JD, Peebles RS Jr, et al
    Infant Infection With Respiratory Syncytial Virus Genotypes and Subsequent Childhood Asthma Risk.
    J Infect Dis. 2026;234:e34-e39.
    PubMed         Abstract available
    
    
15. KACHIKIS A, Frivold C, Pike M, Reed JC, et al
    Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.
    J Infect Dis. 2026 Mar 26:jiag111. doi: 10.1093.
    PubMed         Abstract available
    
    
16. KOBERSSY Z, Daher J, Durieux JC, Atieh O, et al
    Comparison of Immune Activation and Gut Barrier Dysfunction between Long COVID and HIV infection.
    J Infect Dis. 2026 Mar 31:jiag146. doi: 10.1093.
    PubMed         Abstract available
    
    
17. FEYS S, Heylen J, Goncalves SM, Pereira I, et al
    Genetic variation in the long pentraxin PTX3 and Dectin-1 does not predispose to influenza- or COVID-19-associated pulmonary aspergillosis.
    J Infect Dis. 2026 Aug 7:jiag403. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

18. ALSHAMMARI AO, Alshammari HO, Ali H, Himmat B, et al
    A flexible exponential type family for modeling non-monotonic hazard rates with application to mortality analysis: A COVID-19 case study.
    PLoS One. 2026;21:e0331050.
    PubMed         Abstract available
    
    
19. GOURAUD C, Guemouni S, Thoreux P, Ouazana-Vedrines C, et al
    Health-related quality of life among patients with long COVID according to the presence of a diagnosis of functional somatic disorder: A cross-sectional study.
    PLoS One. 2026;21:e0354238.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. ZHOU J, Li W, Wang X, Sun J, et al
    A structural and mechanistic atlas of NTD antibody neutralization and immune escape across SARS-CoV-2 prototype and its (sub-)variants.
    Proc Natl Acad Sci U S A. 2026;123:e2535385123.
    PubMed         Abstract available
    
    
21. MULLER L, Sartori F, Dehning J, Eggl MF, et al
    Optimizing infectious disease mitigation under dynamic conditions.
    Proc Natl Acad Sci U S A. 2026;123:e2527395123.
    PubMed         Abstract available
    
    

    
    Vaccine

22. XU N, Wang L, Zhao C, Shen Y, et al
    Advances in clinical immunogenicity evaluation of influenza vaccines.
    Vaccine. 2026;89:128989.
    PubMed         Abstract available